Blockade of Voltage-Dependent K+ Channels by Benztropine, a Muscarinic Acetylcholine Receptor Inhibitor, in Coronary Arterial Smooth Muscle Cells. (9th August 2022)

• Record Type: Journal Article
• Authors: Kang, Minji; An, Jin Ryeol; Li, Hongliang; Zhuang, Wenwen; Heo, Ryeon; Park, Seojin; Mun, Seo-Yeong; Park, Minju; Seo, Mi Seon; Han, Eun-Taek; Han, Jin-Hee; Chun, Wanjoo; Park, Won Sun
• Is Part Of: Toxicological sciences. Volume 189:Number 2(2022)
• Page Start: 260
• Page End: 267
• Publication Date: 2022-08-09
• Subjects: benztropine -- voltage-dependent K+ -- channel -- coronary arterial smooth muscle -- use-dependent; Toxicology -- Periodicals; Toxicology -- Periodicals; Toxicology; Periodicals; 615.9
• DOI: 10.1093/toxsci/kfac083
• Languages: English
• ISSNs: 1096-6080

Abstract

Abstract: We investigated the effect of the acetylcholine muscarinic receptor inhibitor benztropine on voltage-dependent K + (Kv) channels in rabbit coronary arterial smooth muscle cells. Benztropine inhibited Kv currents in a concentration-dependent manner, with an apparent IC50 value of 6.11 ± 0.80 μM and Hill coefficient of 0.62 ± 0.03. Benztropine shifted the steady-state activation curves toward a more positive potential, and the steady-state inactivation curves toward a more negative potential, suggesting that benztropine inhibited Kv channels by affecting the channel voltage sensor. Train pulse (1 or 2 Hz)-induced Kv currents were effectively reduced by the benztropine treatment. Furthermore, recovery time constants of Kv current inactivation increased significantly in response to benztropine. These results suggest that benztropine inhibited vascular Kv channels in a use (state)-dependent manner. The inhibitory effect of benztropine was canceled by pretreatment with the Kv 1.5 inhibitor, but there was no obvious change after pretreatment with Kv 2.1 or Kv7 inhibitors. In conclusion, benztropine inhibited the Kv current in a concentration- and use (state)-dependent manner. Inhibition of the Kv channels by benztropine primarily involved the Kv1.5 subtype. Restrictions are required when using benztropine to patients with vascular disease.